Financial PerformanceMcKesson missed FY4Q24 operationally on multiple fronts, then followed up with an even worse FY1Q25 that included negative revenue and AOI variances in US Pharma, Med-Surg, and Prescription Tech, with several negative operating guidance adjustments.
Investor ConcernsOddly, investors have been clamoring for more access and transparency from MCK, though this initiative to provide access has proved to be clumsy and further frustrated investors.
Revenue GuidanceThe company reduced its revenue guidance in its Med-Surg business, pointing to normalization of market conditions and lower volumes.